David Risinger
Stock Analyst at Leerink Partners
(3.41)
# 322
Out of 5,270 analysts
195
Total ratings
62.96%
Success rate
44.93%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Regeneron Pharmaceut... | Upgrades: Outperform | 762 834 | 687.82 | 21.25% | 8 | Feb 5, 2025 | |
Johnson & Johnson | Maintains: Outperform | 182 169 | 166.34 | 1.6% | 3 | Jan 23, 2025 | |
AbbVie | Upgrades: Outperform | 206 | 211.25 | -2.49% | 7 | Nov 22, 2024 | |
Bristol-Myers Squibb | Upgrades: Outperform | 55 73 | 59.63 | 22.42% | 4 | Nov 12, 2024 | |
Tectonic Therapeutic | Maintains: Outperform | 49 69 | 24 | 187.5% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 16 | 5.75 | 178.26% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 44 | n/a | n/a | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 106 153 | 72.73 | 110.37% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 15 10 | 9.17 | 9.05% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 28 2 | 1.75 | 14.29% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 47 | 15.01 | 213.12% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 267 318 | 309.49 | 2.75% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 6 11 | 15.16 | -27.44% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 410 458 | 927.19 | -50.6% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 42 | 58.4 | -28.08% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 374 365 | 488.13 | -25.22% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 81 91 | 115.85 | -21.45% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 49 48 | 26.02 | 84.47% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 8 10 | 10.31 | -3.01% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 88 117 | n/a | n/a | 12 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 7 10 | 13.57 | -26.31% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 35 37 | 14.28 | 159.1% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 162 176 | 141.09 | 24.74% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 16 | 9.38 | 70.58% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 53 45 | 29.08 | 54.75% | 7 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 5 7 | n/a | n/a | 8 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 22 35 | 7.08 | 394.35% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 31 41 | 11.2 | 266.07% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 167 174 | 169 | 2.96% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 51 | 33.83 | 50.75% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 8 | 16 | -50% | 14 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 23 18 | n/a | n/a | 12 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 97 89 | 92.7 | -3.99% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 16 | 34.27 | -53.31% | 6 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 5 3 | 8.89 | -66.25% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 156 | n/a | n/a | 8 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 14 35 | n/a | n/a | 5 | Aug 17, 2018 |